Citadel Advisors’s Obsidian Therapeutics OBX Stock Holding History
Bought
Maintained
Sold
Other funds holding OBX
Citadel Advisors's OBX Position: Q3 2026 in Review
Citadel Advisors opened a new position in Obsidian Therapeutics (OBX) in Q3 2026: 1,947,843 shares worth $26.7M. The stake represents ﹤0.01% of the portfolio and ranks #2255 among its holdings.
60 funds tracked by Wall St. Rank hold OBX as of Q3 2026.
- Citadel Advisors held 1,947,843 shares of Obsidian Therapeutics worth $26.7M as of Q3 2026.
- Obsidian Therapeutics was a new Citadel Advisors position in Q3 2026.
- Obsidian Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #2255 holding.
- 60 funds tracked by Wall St. Rank held Obsidian Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.